ReCode Therapeutics

ReCode Therapeutics

Biotechnology Research

Powering the next wave of genetic medicines through superior delivery

About us

ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Menlo Park, California & Durham, North Carolina
Type
Privately Held
Founded
2015
Specialties
RNA Therapies, Genetic Medicines, Non-Viral Lipid Nanoparticles, Genetic Respiratory Disease, Cystic Fibrosis, Primary Ciliary Dyskinesia, and Biotechnology

Locations

Employees at ReCode Therapeutics

Updates

Similar pages

Browse jobs

Funding